Alzamend Neuro Inc. Common Stock (ALZN)

About ALZN

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerati…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

4

Website

alzamend.com/

Fundamentals

1-day range

$1.64$1.72

Market cap

$6.42M

P/E (trailing)

—

P/E (forward)

-1.91

EPS (trailing)

$-2.88

Dividend yield

—

Beta

0.35

Avg. volume

155.8K

Forecasts

1 analyst ratings

Alzamend Neuro Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ALZN

  Alzamend Neuro Inc. Common Stock

  $1.66

  ▼ 0.30%
  Market cap $6.42MP/E —
  $0.84$2.68
• ACXP

  Acurx Pharmaceuticals Inc. Common Stock

  $1.45

  ▼ 1.03%
  Market cap $6.15MP/E —
  $1.31$8.34
• HCWB

  HCW Biologics Inc. Common Stock

  $3.39

  ▲ 6.94%
  Market cap $6.06MP/E —
  $1.5$38.16
• PCSA

  Processa Pharmaceuticals Inc. Common Stock

  $2.07

  ▼ 1.90%
  Market cap $7.09MP/E —
  $1.67$14.24
• TRAW

  Traws Pharma Inc. Common Stock

  $0.59

  ▲ 0.00%
  Market cap $7.18MP/E —
  $0.4301$3.27
• JUNS

  Jupiter Neurosciences Inc. Common Stock

  $4.59

  ▼ 6.13%
  Market cap $5.65MP/E —
  $4.1$138
• NCNA

  NuCana plc American Depositary Share

  $1.79

  ▲ 21.43%
  Market cap $5.62MP/E 0.01
  $1.21$7.22

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Alzamend Neuro Files Prospectus Related To The Resale Of Up To 98.4M Common Shares By Selling Stockholder
  benzinga · 8/21/2026
• Alzamend Neuro Files Prospectus Related To The Resale Of Up To 98.4M Common Shares By Selling Stockholder
  Benzinga · 8/21/2026
• Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC
  Yahoo · 8/20/2026
• Alzamend Neuro Announces Its Abstract On Resting-State Functional Magnetic Resonance Imaging Findings For AL001 Accepted For Presentation At Neuroscience 2026
  Benzinga · 8/20/2026
• Palo Alto To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday
  Benzinga · 8/19/2026
• Ascendiant Capital Maintains Buy on Alzamend Neuro, Raises Price Target to $26
  Benzinga · 8/19/2026
• Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain
  Yahoo · 8/18/2026
• Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop
  Benzinga · 8/18/2026
• Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending
  Yahoo · 8/4/2026

• Hyperscale Data, Inc. · July 31, 2026 · Grant

  7.5K @ $1,000
• Milton C. Ault III · July 31, 2026 · Grant

  7.5K @ $1,000
• Milton C. Ault III · April 14, 2026 · Buy

  108.4K @ $1

Institutional Ownership

March 31, 2026

Total shares held

94.5K

Total value held

$100.1K

Institutional holders

11